Publications by authors named "S Culine"
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials.
Clin Genitourin Cancer
April 2025
Introduction: A post hoc analysis of efficacy and safety outcomes with pembrolizumab monotherapy was conducted in patients with advanced or metastatic urothelial carcinoma (UC) with pure transitional cell carcinoma (TCC) or mixed predominant TCC histology enrolled in the phase 3 KEYNOTE-045 and KEYNOTE-361 studies.
Methods: Adults with platinum-refractory advanced or metastatic UC who received pembrolizumab monotherapy in KEYNOTE-045 and adults with advanced or metastatic UC and no prior systemic chemotherapy who received pembrolizumab monotherapy in KEYNOTE-361 were analyzed separately. Pembrolizumab 200 mg was administered intravenously every 3 weeks for ≤2 years.
Purpose: Emerging therapies including anti-PD-(L)1 immunotherapy have changed paradigms of treatment and improved oncological outcomes of advanced/metastatic urothelial carcinoma (mUC) patients. An emerging challenge in this setting is the management of isolated urinary tract persistence or progression (IUTP) of primary urothelial tumor despite stability or response of metastatic disease to immunotherapy.
Methods: This retrospective monocentric study included all patients treated with single-agent anti-PD-(L)1 for mUC between August 2015 and October 2023.
Aim: Describe real-world epidemiology, treatment patterns, health care resource utilization, and costs of locally advanced or metastatic urothelial carcinoma (la/mUC) in France.
Patients & Methods: Retrospective study including all adults with la/mUC diagnosis during January 2017 to December 2020 in the PMSI database.
Results: Annual prevalence and incidence ranged from 36.
Article Synopsis
- The study looked at health literacy (HL) in cancer patients aged 65 and older compared to those aged 18-64 in France.
- It found that older patients used digital tools less often and had lower HL scores than younger patients.
- The results suggest that it's really important for doctors to pay attention to health literacy so they can help patients understand their health better, especially those who may struggle with it.
Article Synopsis
- * This study evaluated 300 patients from the GETUG/AFU VESPER trial, identifying various molecular subtypes of tumors and their association with treatment outcomes, particularly focusing on the Basal/squamous subtype and Mixed tumors.
- * Results showed that Basal/squamous patients had a higher risk of progression after NAC, and Mixed tumors suggested chemoresistance, with limited immune response changes observed in certain molecular subtypes post-treatment.